12 results about "Human sequence" patented technology

The application provides an anti-Spike protein antibody of a novel coronavirus and an application thereof. By means of genetic engineering and phage surface display library technology, specific antibodies against the S protein of the novel coronavirus are screened from a single-chain antibody library of non-immune full human sequences. The antibodies have an affinity to the S protein of the virus between 1nM and 50nM, the antibodies have an inhibiting effect on the combination of the S protein of the novel coronavirus and human receptor ACE2, and the anti-S protein antibodies of the application have a good ability to combine with the S protein and a potential neutralizing inhibiting effect. The application provides specific antibody candidate molecules for the development of diagnostic reagents, preventive and therapeutic antibody drugs against the novel coronavirus (2019-nCoV) and the treatment of other diseases such as pneumonia caused by the coronavirus.

The application provides an anti-Spike protein antibody of a novel coronavirus and an application thereof. By means of genetic engineering and phage surface display library technology, specific antibodies against the S protein of the novel coronavirus are screened from a single-chain antibody library of non-immune full human sequences. The antibodies have an affinity to the S protein of the virus between 1nM and 50nM, the antibodies have an inhibiting effect on the combination of the S protein of the novel coronavirus and human receptor ACE2, and the anti-S protein antibodies of the application have a good ability to combine with the S protein and a potential neutralizing inhibiting effect. The application provides specific antibody candidate molecules for the development of diagnostic reagents, preventive and therapeutic antibody drugs against the novel coronavirus (2019-nCoV) and the treatment of other diseases such as pneumonia caused by the coronavirus.

Proteases of Group IV (+)ssRNA viruses were found to act on a human sequences in addition to the viral sequences. The identity of the cleavable human sequences is disclosed. Detection of these sequences can act as a diagnostic of infection. It is contemplated that these findings could be employed to facilitate post-translational silencing at the level of protein (e.g., removal of existing proteins), thus serving as a protein analog to CRISPR / Cas9 and RNAi / RISC, and further to enable sequence-specific silencing of host functions without the modification of the host genome.

The invention discloses a blocking agent for eliminating environmental DNA (Deoxyribose Nucleic Acid) of human pollution and a detection method of the environmental DNA, and the blocking agent plays a role in inhibiting amplification of a human source sequence by specifically hybridizing with a human source template and blocking primer annealing or DNA polymerase extension. The invention further provides application of the CRISPR-Cas12a technology to in-vitro removal of human-derived DNA pollution, the method can reduce the sequencing cost and the time cost of bioinformatics processing without affecting detection of target biological groups, and the method is mainly used for treating human pollution in marine environment DNA. And the method can also be used for treating human-derived DNA pollution in similar molecular biology research and application.

Compositions, kits, and methods are provided for validating patient-specific oligonuclotide assays using spike-in controls. The compositions comprise multiple sets of spike-in oligos, each set including a unique reference sequence and near-neighbor sequences with at least one substitution, insertion, or deletion. Near-neighbor concentrations are less than the reference and collectively span at least four orders of magnitude (e.g., 1:10 to 1:10,000); all sets have the same number of near-neighbors and concentration ratios. Spike-in sequences are unrelated to human sequences and are complementary to synthesis-control oligos at known concentrations. Kits further include synthesis-control oligos and patient-specific oligos for human DNA or RNA targets. Methods involve spiking a sample, co-synthesizing control and patient-specific oligos, assaying by PCR or sequencing, and validating limit of detection and dynamic range by comparing observed counts to known ratios. Applications include ctDNA and cfRNA testing.

The application relates to the technical field of biological industry, and discloses an analysis method for HBV expression level and fragment distribution based on single-cell RNA-seq, constructs position information of each gene of HBV in a linear transcriptome and a circular genome, and obtains a mapping relationship of the transcriptome and the genome; compares original sequencing data obtained by scRNA-seq to an HBV transcriptome reference sequence, identifies human sequences and HBV sequences, removes the human sequences, and obtains HBV source transcriptome sequences; converts the position of the sequencing sequence on the transcriptome into a comparison position on the genome through the mapping relationship of the transcriptome and the genome; calculates the number of sequencing sequences covered on each base of the genome, draws the coverage depth of each base of the HBV genome, and obtains the expression level and fragment distribution of single-cell RNA-seq sequencing data on the HBV genome. The application fills the blank of the HBV analysis method based on single-cell resolution.

The invention discloses a multiple PCR primer design method for drug-resistant mutation targeted detection and application thereof, and belongs to the field of biotechnology primer design, the method comprises the following steps: determining a drug-resistant gene of a target species and a detection site thereof; generating a primer set on the basis of one step length based on the target sequence position of the drug-resistant gene mutation site; the candidate primer is subjected to primer attribute evaluation such as TM value, primer length and GC content; meanwhile, a specific sequence is obtained through human-derived sequence non-specific amplification evaluation, dimer evaluation and comparison of a candidate primer and a nt library, the primer coverage degree is evaluated based on a species genome, a conservative primer sequence is obtained, and finally, a final target drug-resistant gene mutation site primer is obtained based on a mutation frequency result. The method is wide in applicability, parallel detection of multiple drug-resistant genes in a single cell can be achieved, and a new strategy is provided for developing design of multiple PCR system primers for drug-resistant mutation targeted detection.

The invention discloses a construction method and application of an IL22 gene humanized animal, and relates to the technical field of biology. The construction method is characterized in that a whole genome sequence of exons 1-5 of a non-human animal Il22 gene is replaced by a whole genome sequence of exons 1-5 of a human IL22 gene, and a non-human animal genome contains a human sequence shown as SEQ ID NO.4. The construction method comprises the following steps: firstly, constructing a human-derived sequence; an ideal in-vivo research platform is provided for deeply researching a human IL22 signal channel mechanism and screening tumor and immune disease treatment medicines.

The present application relates to a tumor risk prediction method and device based on cfDNA nucleosome fingerprint, belonging to the technical field of in vitro diagnosis. Among them, the method comprises: obtaining whole genome sequencing data of plasma or serum cfDNA; the whole genome sequencing data is subjected to quality control processing to remove non-human sequences to obtain human cfDNA sequencing fragments; the human cfDNA sequencing fragments are aligned to the human reference genome to obtain the genomic coordinates of each fragment and the coverage information thereof on the reference genome; based on the whole genome coverage signal, the enrichment region identification algorithm is used to determine the nucleosome positioning boundary, and the peak signal strength is taken as the nucleosome positioning intensity score; the nucleosome positioning intensity score is input into the tumor risk prediction model which has been trained, and the prediction risk probability of the subject suffering from tumor is output. Greatly improve the accuracy of noninvasive screening tumor prediction tumor risk, and the detection cost is low and the cycle is short.

The embodiment discloses a computer-assisted method for evaluating and modifying immunogenicity, as well as related computer systems and storage media. The method includes using unsupervised learning of a protein large language model on all human sequences and a supervised deep learning neural networks to establish a predictive scoring model for the humanness score of peptide chains based on the data from the model training dataset to achieve classification between human and non-human species. This involves cutting protein sequences into all possible peptide chains of a preset length using a dynamic window method and importing these chains into the predictive scoring, thereby evaluating their immunogenicity in terms of humanness score. Peptide chains with scores above a certain threshold undergo all possible single-point virtual mutations to generate a set of modified peptide chains which are then reassessed using the model, selecting those with scores above the threshold of humanness for further consideration.

The invention provides a recombinant human collagen type II COLII-23k. The amino acid sequence of the recombinant human collagen type II COLII-23k is as shown in SEQ ID NO. 1. The invention also provides a pichia pastoris engineering bacterium for expressing the collagen COLII-23k, the engineering bacterium comprises a gene for coding the COLII-23k, and the coding gene is connected to a pichia pastoris expression vector in a seamless cloning manner. Meanwhile, the invention also provides an application of the collagen COLII-23k. The invention has the advantages that the active fragment COLII-23k of the human collagen type II provided by the invention is a complete human sequence, does not have redundant amino acid, and has excellent hemostatic activity and skin cell proliferation, adhesion and migration promotion functions; pichia pastoris engineering bacteria for expressing the protein are constructed through seamless cloning, the expression quantity is high, and industrial production is easy; and the collagen is wide in application scene, and can meet the requirements of multiple fields such as hemostasis, wound repair and medical beauty.

The application discloses synthesis of type XVII humanized collagen and a preparation method and application thereof, and particularly relates to the technical field of genetic engineering. The amino acid sequence of the recombinant type XVII collagen is shown as SEQ ID NO. 1. The application retains key functional domains (5 high-hydrophilicity and high-stability peptide segments of 641-685) in the alpha 1 chain of human type XVII collagen, and eliminates non-functional regions. The application adopts 100% human sequence coverage, completely avoids the immunogenicity risk of animal-derived collagen, and has excellent biocompatibility. The functional peptide segments are repeated twice to form a stable structure of 210 amino acids, and the protein functional activity is enhanced. The theoretical isoelectric point (pI=6.07) is close to the pH (7.4) of human tissue fluid, the solubility is excellent, and the applicability is strong.